| __timestamp | Protagonist Therapeutics, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 504755000 |
| Thursday, January 1, 2015 | 2963000 | 838526000 |
| Friday, January 1, 2016 | 6961000 | 1177697000 |
| Sunday, January 1, 2017 | 11779000 | 1320433000 |
| Monday, January 1, 2018 | 13697000 | 1556200000 |
| Tuesday, January 1, 2019 | 15749000 | 1834800000 |
| Wednesday, January 1, 2020 | 18638000 | 1346000000 |
| Friday, January 1, 2021 | 27196000 | 1824900000 |
| Saturday, January 1, 2022 | 31739000 | 2115900000 |
| Sunday, January 1, 2023 | 33491000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Regeneron consistently reported higher SG&A expenses, peaking at approximately $2.63 billion in 2023. Despite this, their expenses grew at a modest rate of around 5% annually, reflecting a strategic balance between growth and cost control. In contrast, Protagonist Therapeutics, with a smaller scale, saw its SG&A expenses surge by over 1,700% during the same period, reaching $33.5 million in 2023. This rapid increase highlights their aggressive expansion strategy.
Understanding these trends offers valuable insights into how biotech companies navigate financial management, balancing innovation with operational efficiency.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?